Key result
Antiarrhythmic drugs offer viable treatment options for arrhythmias during pregnancy when conservative therapies fail, requiring careful consideration of maternal and fetal risks and benefits.
Why the study?
What are the safety and efficacy considerations for using antiarrhythmic drugs in pregnant women with arrhythmias?
What are the safety and efficacy considerations for using antiarrhythmic drugs in pregnant women with arrhythmias?
Antiarrhythmic drugs provide a necessary treatment option for pregnant women with arrhythmias unresponsive to conservative therapy, though risks and benefits must be carefully weighed.
Answers are grounded in this paper and cite their sources.
May guide antiarrhythmic selection in refractory pregnancy arrhythmias; leaves open need for prospective safety data.
The risk of arrhythmia development or recurrence is increased during pregnancy. For those arrhythmias that are unresponsive to conservative therapy, such as vagal maneuvers or life style interventions, or that present a higher risk to the mother or fetus, medical therapy may be necessary. In each case, the patient and provider must carefully consider the risks and benefits of a particular therapy. This requires an understanding of the data regarding the safety and efficacy of any particular drug, which in some cases may be extensive and in others quite limited. Fortunately, options exist for the treatment of arrhythmias during pregnancy.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2015) conducted a review in Arrhythmia during pregnancy. Antiarrhythmic drugs was evaluated. Antiarrhythmic drugs offer viable treatment options for arrhythmias during pregnancy when conservative therapies fail, requiring careful consideration of maternal and fetal risks and benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: